ReviewDrugs in R&D2023

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.

Martin Vališ et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.